Search results
Results from the WOW.Com Content Network
Lipodystrophy can appear as a lump or small dent in the skin that forms when a person performs injections repeatedly in the same spot. These types of lipodystrophies are harmless and can be avoided by changing (rotating) the locations of injections. For those with diabetes, using purified insulins and new needles with each injection may also help.
Lipoatrophy. Lipoatrophy is the term describing the localized loss of fat tissue. This may occur as a result of subcutaneous injections of insulin in the treatment of diabetes, from the use of human growth hormone or from subcutaneous injections of copaxone used for the treatment of multiple sclerosis. In the latter case, an injection may ...
Acquired generalized lipodystrophy (AGL), also known as Lawrence syndrome[1] and Lawrence–Seip syndrome, [1] is a rare skin condition that appears during childhood or adolescence, characterized by fat loss affecting large areas of the body, particularly the face, arms, and legs. [2]: 496 There are four types of lipodystrophy based on its ...
Localized lipodystrophy. Specialty. Dermatology. Localized lipodystrophy is a skin condition characterized by the loss of subcutaneous fat localized to sites of insulin injection. [1]: 497.
They are harmless. See also: Lipoatrophy; injection site rotation. Insulin-induced hypertrophy Small lumps that form under the skin when a person keeps injecting a needle in the same spot. See also: Lipodystrophy; injection site rotation. Insulin pen An insulin injection device the size of a pen that includes a needle attached to a vial of insulin.
Insulin aspart. Insulin aspart, sold under the brand name NovoLog, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. [17] It is generally used by injection under the skin but may also be used by injection into a vein. [17] Maximum effect occurs after about 1–3 hours and lasts for 3–5 hours. [17]
The main difference was that reactions at the injection site occurred more frequently in people who received lerodalcibep (6.9%) compared to those in the placebo group (0.3%). These reactions were ...
Lipohypertrophy[1] is a lump under the skin caused by accumulation of extra fat at the site of many subcutaneous injections of insulin. It may be unsightly, mildly painful, and may change the timing or completeness of insulin action. It is a common, minor, chronic complication of diabetes mellitus. Typical injection site hypertrophy is several ...